title: Platelet refractoriness due to combined anti-HLA and anti-HPA-5a alloantibodies: clinical management during myeloablative allogeneic HSCT and development of a quantitative MAIPA assay.
authors.affiliation: Haematology, University Hospital Basel, Switzerland. arberc@uhbs.ch
authors.forename: Caroline
authors.initials: C
authors.lastname: Arber
authors.forename: Gerald
authors.initials: G
authors.lastname: Bertrand
authors.forename: Jörg
authors.initials: J
authors.lastname: Halter
authors.forename: Françoise
authors.initials: F
authors.lastname: Boehlen
authors.forename: Cécile
authors.initials: C
authors.lastname: Kaplan
authors.forename: Alois
authors.initials: A
authors.lastname: Gratwohl
mesh_terms: D000208:Acute Disease; D016824:Antigens, Human Platelet / Q000276:immunology*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D005260:Female; D006680:HLA Antigens / Q000276:immunology*; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D007518:Isoantibodies / Q000032:analysis*; D007951:Leukemia, Myeloid / Q000276:immunology* / Q000628:therapy*; D008875:Middle Aged; D017713:Platelet Transfusion; D014184:Transplantation, Homologous; D017211:Treatment Failure
chemical_list: C071092:5a alloantigen, human; D016824:Antigens, Human Platelet; D006680:HLA Antigens; D007518:Isoantibodies